


10/518652

DT01 Rec'd PCT/PTC 16 DEC 2004

In the Claims:

1. (original) Compound of formula (I):







in which

X represents N or CH;



R₁ represents a hydrogen or halogen atom or a CF₃ group;R₂ and R₃ independently represent a hydrogen atom or a methyl group;

n is 0 or 1;

W represents a diazoheterocycle of formula (a) to (d)



A represents a group of formula (e) or (f)




where


- R₄ represents a hydrogen or halogen atom, a (C₁-C₄)alkyl group, a CF₃ group, an amino, a mono(C₁-C₄)alkylamino or a di(C₁-C₄)alkylamino group;
- R₅ represents a hydrogen or halogen atom, a (C₁-C₄)alkoxy group, a (C₁-C₄)alkyl group or a CF₃ group;
- R₆ represents a hydrogen atom, a (C₁-C₄)alkyl group or a (C₁-C₄)alkoxy group; it being possible for only one or both of the atoms of the rings (a) to (d) to be oxidized;
- and their salts or solvates.

2. **(original)** Compound according to Claim 1, where n is zero.
3. **(currently amended)** Compound according to Claim 1 ~~or 2, where~~ wherein R₂ and R₃ are each a hydrogen atom.
4. **(currently amended)** Compound according to Claim 1 ~~or 2, where~~ wherein R₁ is a CF₃ group.
5. **(currently amended)** Compound according to Claim 1 ~~or 2, where~~ wherein R₁ is a fluorine or chlorine atom.
6. **(currently amended)** Compound according to ~~Claims 1 to 3, where~~ Claim 1 wherein X is CH and R₁ is at the 3-position of the benzene.
7. **(currently amended)** Compound according to ~~Claims 1 to 3, where~~ Claim 1 wherein X is CH and R₁ is at the 2-position of the benzene.
8. **(currently amended)** Compound according to ~~Claims 1 to 3, where~~ Claim 1 wherein X is N and the pyridine is substituted at the 2,6-positions.
9. **(currently amended)** Compound according to ~~Claims 1 to 8,~~ Claim 1 chosen from its mono-N-oxide derivatives, its bis-N-oxides and its tri-N-oxides.

10. **(currently amended)** ~~Method~~ A method for preparing the compound of Claim 1; ~~characterized in that wherein~~ there are carried out a condensation/reduction reaction of a compound of formula (II):




in which X, W and R₁ are as defined in Claim 1, with an aldehyde of formula (III):



in which R₂, R₃, n and A are as defined above, the isolation of the compound of formula (I) and the optional conversion to one of its salts or solvates or to its N-oxide derivatives.

11. **(original)** Compound of formula (II')



in which W represents a group of formula (b) or (c) according to Claim 1, and its salts or solvates.

12. **(currently amended)** ~~Pharmaceutical~~ A pharmaceutical composition containing, as active ingredient, a compound of formula (I) according to ~~Claims 1 to 9~~ Claim 1 or one of its pharmaceutically acceptable salts or solvates.

13. **(currently amended)** Composition according to Claim 12, ~~characterized in that wherein~~ it contains from 0.001 to 100 mg of active ingredient.

14. **(currently amended)** ~~Use of a compound of formula (I) according to Claims 1 to 9 or of one of its pharmaceutically acceptable salts or solvates for the preparation of analgesic medicaments and/or intended~~ A method for the treatment of diseases linked to immune and inflammatory disorders or for the treatment of pain which comprises administering to a patient in need thereof an effective amount of a compound according to claim 1.

15. **(cancelled)**

16. **(new)** Compound according to Claim 2 wherein R_2 and R_3 are each a hydrogen atom.

17. **(new)** Compound according to Claim 2 wherein R_1 is a CF_3 group.

18. **(new)** Compound according to Claim 2 wherein R_1 is a fluorine or chlorine atom.

19. **(new)** Compound according to Claim 2 wherein X is CH and R_1 is at the 3-position of the benzene.

20. **(new)** Compound according to Claim 3 wherein X is CH and R_1 is at the 3-position of the benzene.

21. **(new)** Compound according to Claim 2 wherein X is CH and R_1 is at the 2-position of the benzene.

22. **(new)** Compound according to Claim 3 wherein X is CH and R_1 is at the 2-position of the benzene.

23. **(new)** Compound according to Claim 2 wherein X is N and the pyridine is substituted at the 2,6-positions.

24. **(new)** Compound according to Claim 3 wherein X is N and the pyridine is substituted at the 2,6-positions.

25. **(new)** A pharmaceutical composition containing, as active ingredient, a compound of formula (I) according to Claim 2 or one of its pharmaceutically acceptable salts or solvates.
26. **(new)** A pharmaceutical composition containing, as active ingredient, a compound of formula (I) according to Claim 3 or one of its pharmaceutically acceptable salts or solvates.
27. **(new)** A pharmaceutical composition containing, as active ingredient, a compound of formula (I) according to Claim 4 or one of its pharmaceutically acceptable salts or solvates.
28. **(new)** A pharmaceutical composition containing, as active ingredient, a compound of formula (I) according to Claim 5 or one of its pharmaceutically acceptable salts or solvates.
29. **(new)** A pharmaceutical composition containing, as active ingredient, a compound of formula (I) according to Claim 6 or one of its pharmaceutically acceptable salts or solvates.
30. **(new)** A pharmaceutical composition containing, as active ingredient, a compound of formula (I) according to Claim 7 or one of its pharmaceutically acceptable salts or solvates.
31. **(new)** A pharmaceutical composition containing, as active ingredient, a compound of formula (I) according to Claim 8 or one of its pharmaceutically acceptable salts or solvates.
32. **(new)** A pharmaceutical composition containing, as active ingredient, a compound of formula (I) according to Claim 9 or one of its pharmaceutically acceptable salts or solvates.
33. **(new)** A method for the treatment of diseases linked to immune and inflammatory disorders or for the treatment of pain which comprises administering to a patient in need thereof an effective amount of a compound according to claim 2.
34. **(new)** A method for the treatment of diseases linked to immune and inflammatory disorders or for the treatment of pain which comprises administering to a patient in need thereof an effective amount of a compound according to claim 3.
35. **(new)** A method for the treatment of diseases linked to immune and inflammatory disorders or for the treatment of pain which comprises administering to a patient in need thereof an effective amount of a compound according to claim 4.

36. **(new)** A method for the treatment of diseases linked to immune and inflammatory disorders or for the treatment of pain which comprises administering to a patient in need thereof an effective amount of a compound according to claim 5.

37. **(new)** A method for the treatment of diseases linked to immune and inflammatory disorders or for the treatment of pain which comprises administering to a patient in need thereof an effective amount of a compound according to claim 6.

38. **(new)** A method for the treatment of diseases linked to immune and inflammatory disorders or for the treatment of pain which comprises administering to a patient in need thereof an effective amount of a compound according to claim 7.

39. **(new)** A method for the treatment of diseases linked to immune and inflammatory disorders or for the treatment of pain which comprises administering to a patient in need thereof an effective amount of a compound according to claim 8.

40. **(new)** A method for the treatment of diseases linked to immune and inflammatory disorders or for the treatment of pain which comprises administering to a patient in need thereof an effective amount of a compound according to claim 9.